Rocket Lab’s Government Wins Pile Up as the Stock Tumbles

Rocket Lab is firing on all operational cylinders — launching satellites for loyal customers, securing NASA science missions, joining the Nasdaq-100, and even landing a slot in a U.S. Space Force program. Yet the stock has shed more than 40% in a month, exposing a yawning gap between corporate execution and investor sentiment.

The company’s fundamental story has rarely been stronger. First-quarter 2026 revenue hit $200.3 million, a 63.5% jump year-over-year, while the backlog swelled to a record $2.2 billion. More than 70 missions are on the manifest, underpinned by repeat business from the likes of Japanese Earth-observation specialist Synspective. The tenth dedicated Electron launch for that customer — internally dubbed “Ten Owl Of Ten” — lifted off from Māhia Peninsula on the latest Friday, bringing Rocket Lab’s total completed missions to 91. Another 17 Synspective launches remain booked through the end of the decade.

The week also brought two high-profile contract wins. NASA selected Rocket Lab on June 25 for the PolSIR and TSIS-2 science missions, both to fly on Electron from New Zealand. PolSIR could launch as early as June 2027, with TSIS-2 expected in early 2027. The underlying indefinite-delivery/indefinite-quantity framework has a ceiling of $300 million over ten years. A day later, the company appeared in a U.S. Space Force procurement database for the SB-AMTI (Space-Based Airborne Moving Target Indicator) program — but the contract amount raised eyebrows at just $10,000. While SpaceX landed a $4.16 billion award in May, Rocket Lab’s nomination to the vendor pool alongside Lockheed Martin, Northrop Grumman, and L3Harris is a procedural foothold. The Space Systems Command plans to issue follow-on contracts next year as it builds a satellite constellation by 2028, meaning the small prototype study could lead to bigger prizes.

Another milestone arrived on June 22 when Rocket Lab was added to the Nasdaq-100 Index, alongside Astera Labs, CoreWeave, Nebius Group, and Teradyne. Index inclusion typically attracts passive fund flows and raises visibility, yet the stock failed to hold any gains.

Should investors sell immediately? Or is it worth buying Rocket Lab USA?

The price action tells a different story. On the Friday of the Synspective launch, shares gained 6.51% to close at $85.94, but the week still ended nearly 20% lower. The prior Friday, a 4.77% bounce to $84.54 on the SB-AMTI news also proved fleeting. Over 30 days, the stock has lost more than 42%. From the 52-week high of $151.00 reached on May 27, the decline now stands at 43%.

Technically, the chart is under pressure. The 50-day moving average at $105.83 sits well above the current price. The 100-day average at $87.72 was nearly touched on the Friday close but not breached. Downside support lies at the 200-day average of $76.31, roughly 12% below. The relative strength index at 38.2 suggests selling momentum is easing but far from an oversold signal. Annualized 30-day volatility hovers near 100%, amplifying every move.

The disconnect between Rocket Lab’s operational momentum and its share price reflects a broader rotation out of high-growth space stocks, not a company-specific breakdown. Investors appear to be waiting for sustained buying volume to confirm the selloff has run its course. The next technical test is whether the stock can hold the 100-day moving average this week. A clean break above that level would give the recent rebounds credibility; a slide back toward $76 would refocus attention on how deep the sector correction can go.